Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study
暂无分享,去创建一个
[1] M. Cazzaniga,et al. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects , 2020, Cancers.
[2] Piyushkumar A. Mundra,et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy , 2019, Nature Cancer.
[3] M. Jarvis. Therapeutic potential of adenosine kinase inhibition—Revisited , 2019, Pharmacology research & perspectives.
[4] J. Deeks,et al. Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer , 2019, Clinical Cancer Research.
[5] Q. Fu,et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis , 2019, Oncoimmunology.
[6] F. Mannavola,et al. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine , 2019, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[7] Y. Najjar,et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. , 2019, JCI insight.
[8] G. Tabatabai,et al. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. , 2019, Immunotherapy.
[9] C. Loquai,et al. Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters , 2018, Strahlentherapie und Onkologie (Print).
[10] S. Patel,et al. Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy , 2018, Front. Immunol..
[11] P. Romero,et al. CD73 expression and clinical significance in human metastatic melanoma , 2018, Oncotarget.
[12] Kevin B. Kim,et al. Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies , 2018, BMC Cancer.
[13] S. Eichmüller,et al. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E , 2018, Front. Immunol..
[14] A. Niemierko,et al. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity , 2018, Journal of Neuro-Oncology.
[15] M. Smyth,et al. Targeting immunosuppressive adenosine in cancer , 2017, Nature Reviews Cancer.
[16] D. Schadendorf,et al. Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[18] Peter Bankhead,et al. QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.
[19] H. Sugimura,et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer , 2017, Oncotarget.
[20] P. Vaupel,et al. Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck , 2016, British Journal of Cancer.
[21] L. Nardo,et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.
[22] P. Darcy,et al. Immunosuppressive activities of adenosine in cancer. , 2016, Current opinion in pharmacology.
[23] P. Hegde,et al. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.
[24] M. Maio,et al. Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study , 2016, Oncoimmunology.
[25] S. Biswas. Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.
[26] A. Ladányi,et al. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma , 2015, Pigment cell & melanoma research.
[27] F. Malavasi,et al. A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation , 2015, Oncotarget.
[28] A. Bosserhoff,et al. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells , 2015, Oncotarget.
[29] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[30] Akio Ohta,et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation , 2015, Science Translational Medicine.
[31] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[32] N. Bec,et al. Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity , 2014, Cancer Immunology Research.
[33] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[34] J. Utikal,et al. Extracellular adenosine metabolism in immune cells in melanoma , 2014, Cancer Immunology, Immunotherapy.
[35] E. Rofstad,et al. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts , 2012, BMC Cancer.
[36] J. Knisely,et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. , 2012, Journal of neurosurgery.
[37] H. Moch,et al. Tumor Cell Plasticity and Angiogenesis in Human Melanomas , 2012, PloS one.
[38] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[39] B. Seliger,et al. Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumor , 2011, International journal of cancer.
[40] P. Hwu,et al. Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.
[41] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[42] C. Garbe,et al. Determinants of survival in patients with brain metastases from cutaneous melanoma , 2010, British Journal of Cancer.
[43] A. Wree,et al. Solid tumours arising from differently pre-oxygenated cells: Comparable growth rates despite dissimilar tissue oxygenation , 2009, International journal of radiation biology.
[44] Jianzhu Chen,et al. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice , 2008, Proceedings of the National Academy of Sciences.
[45] A. Wree,et al. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. , 2008, Cancer research.
[46] Michael Höckel,et al. Detection and characterization of tumor hypoxia using pO2 histography. , 2007, Antioxidants & redox signaling.
[47] Eva Mezey,et al. Simultaneous Visualization of Multiple Antigens with Tyramide Signal Amplification using Antibodies from the same Species , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[48] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[49] Johan Bussink,et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.
[50] S. Colgan,et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.
[51] G. Barnett,et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma , 2002, Cancer.
[52] F. Eschwège,et al. Intratumoral oxygen tension in metastatic melanoma , 1997, Melanoma research.
[53] H. Lyng,et al. Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[54] C. Balch,et al. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. , 1986, Cancer research.
[55] K. Hellström,et al. Cellular and Humoral immunity to Different Types of Human Neoplasms , 1968, Nature.
[56] Y. Kluger,et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] P. Dundr,et al. Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases , 2017, Pathology & Oncology Research.
[58] P. Vaupel,et al. Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. , 2016, Advances in experimental medicine and biology.
[59] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .